Moneycontrol

Moneycontrol PRO

you are here: HomeNewsBusinessEarningsBiocon Q3 PAT seen up 19%, revenue may grow 20%: Poll

SHOW NAMES

Trending Topics

business

Biocon Q3 PAT seen up 19%, revenue may grow 20%: Poll

Core sales growth of 20 percent will be led by biopharma, India formulations and CRAMS business, analysts say, adding Biopharma will be lead by immunosuppressants (Serolimus) and insulin in emerging markets.

first published: Jan 21, 2014 06:42 pm

LATEST VIDEOS

A collection of the most-viewed Moneycontrol videos.

Watch and Follow our leading shows

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347